SELEGILINE HYDROCHLORIDE

×

Overview

What is SELEGILINE HYDROCHLORIDE?

Selegiline hydrochloride, USP is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.

The chemical name is: (R)-(-)-,2-dimethyl--2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.75. The structural formula is as follows:

Each white opaque capsule is band printed with S 700. Each capsule contains 5 mg selegiline hydrochloride, USP. Inactive ingredients are citric acid, lactose, magnesium stearate and microcrystalline cellulose. The capsule shells contain gelatin and titanium dioxide and are imprinted with red ink. The ink contains pharmaceutical glaze and synthetic red iron oxide.

What does SELEGILINE HYDROCHLORIDE look like?

What are the available doses of SELEGILINE HYDROCHLORIDE?

Sorry No records found.

What should I talk to my health care provider before I take SELEGILINE HYDROCHLORIDE?

Sorry No records found

How should I use SELEGILINE HYDROCHLORIDE?

Selegiline hydrochloride capsules, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy.

Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).

Selegiline hydrochloride capsules are intended for administration to Parkinsonian patients receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment. The recommended regimen for the administration of selegiline hydrochloride is 10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. There is no evidence that additional benefit will be obtained from the administration of higher doses. Moreover, higher doses should ordinarily be avoided because of the increased risk of side effects.

After two to three days of selegiline treatment, an attempt may be made to reduce the dose of levodopa/carbidopa. A reduction of 10 to 30% was achieved with the typical participant in the domestic placebo controlled trials who was assigned to selegiline treatment. Further reductions of levodopa/carbidopa may be possible during continued selegiline therapy.

What interacts with SELEGILINE HYDROCHLORIDE?

Sorry No Records found

What are the warnings of SELEGILINE HYDROCHLORIDE?

Sorry No Records found

What are the precautions of SELEGILINE HYDROCHLORIDE?

Sorry No Records found

What are the side effects of SELEGILINE HYDROCHLORIDE?

Sorry No records found

What should I look out for while using SELEGILINE HYDROCHLORIDE?

Selegiline hydrochloride capsules are contraindicated in patients with a known hypersensitivity to this drug.

Selegiline hydrochloride capsules are contraindicated for use with meperidine (DEMEROL & other trade names). This contraindication is often extended to other opioids. (See )

Selegiline should not be used at daily doses exceeding those recommended (10 mg/day) because of the risks associated with non-selective inhibition of MAO. (See .)

The selectivity of selegiline for MAO-B may not be absolute even at the recommended daily dose of 10 mg a day. Rare cases of hypertensive reactions associated with ingestion of tyramine-containing foods have been reported in patients taking the recommended daily dose of selegiline. The selectivity is further diminished with increasing daily doses. The precise dose at which selegiline becomes a non-selective inhibitor of all MAO is unknown, but may be in the range of 30 to 40 mg a day.

Severe CNS toxicity associated with hyperpyrexia and death have been reported with the combination of tricyclic antidepressants and non-selective MAOIs (NARDIL, PARNATE). A similar reaction has been reported for a patient on amitriptyline and selegiline hydrochloride capsules. Another patient receiving protriptyline and selegiline hydrochloride capsules developed tremors, agitation, and restlessness followed by unresponsiveness and death two weeks after selegiline hydrochloride capsules were added. Related adverse events including hypertension, syncope, asystole, diaphoresis, seizures, changes in behavioral and mental status, and muscular rigidity have also been reported in some patients receiving selegiline hydrochloride capsules and various tricyclic antidepressants.

Serious, sometimes fatal, reactions with signs and symptoms that may include hyperthermia, rigidity, myoclonus, autonomic instability with rapid fluctuations of the vital signs, and mental status changes that include extreme agitation progressing to delirium and coma have been reported with patients receiving a combination of fluoxetine hydrochloride (PROZAC) and non-selective MAOIs. Similar signs have been reported in some patients on the combination of selegiline hydrochloride capsules (10 mg a day) and selective serotonin reuptake inhibitors including fluoxetine, sertraline and paroxetine.

Since the mechanisms of these reactions are not fully understood, it seems prudent, in general, to avoid this combination of selegiline hydrochloride capsules and tricyclic antidepressants as well as selegiline hydrochloride capsules and selective serotonin reuptake inhibitors. At least 14 days should elapse between discontinuation of selegiline hydrochloride capsules and initiation of treatment with a tricyclic antidepressant or selective serotonin reuptake inhibitors. Because of the long half-lives of fluoxetine and its active metabolite, at least five weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses) should elapse between discontinuation of fluoxetine and initiation of treatment with selegiline hydrochloride capsules.

What might happen if I take too much SELEGILINE HYDROCHLORIDE?

Selegiline:

Since the selective inhibition of MAO-B by selegiline hydrochloride is achieved only at doses in the range recommended for the treatment of Parkinson’s disease (e.g., 10 mg/day), overdoses are likely to cause significant inhibition of both MAO-A and MAO-B. Consequently, the signs and symptoms of overdose may resemble those observed with marketed non-selective MAO inhibitors [e.g., tranylcypromine (PARNATE), isocarboxazide (MARPLAN), and phenelzine (NARDIL)].

Overdose with Non-Selective MAO Inhibition:

Characteristically, signs and symptoms of non-selective MAOI overdose may not appear immediately. Delays of up to 12 hours between ingestion of drug and the appearance of signs may occur. Importantly, the peak intensity of the syndrome may not be reached for upwards of a day following the overdose. Death has been reported following overdosage. Therefore, immediate hospitalization, with continuous patient observation and monitoring for a period of at least two days following the ingestion of such drugs in overdose, is strongly recommended.

The clinical picture of MAOI overdose varies considerably; its severity may be a function of the amount of drug consumed. The central nervous and cardiovascular systems are prominently involved.

Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonus, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.

Treatment Suggestions For Overdose: NOTE: Because there is no recorded experience with selegiline overdose, the following suggestions are offered based upon the assumption that selegiline overdose may be modeled by non-selective MAOI poisoning. In any case, up-to-date information about the treatment of overdose can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Poison Control Centers are listed in the Physicians’ Desk Reference (PDR).

Treatment of overdose with non-selective MAOIs is symptomatic and supportive. Induction of emesis or gastric lavage with instillation of charcoal slurry may be helpful in early poisoning, provided the airway has been protected against aspiration. Signs and symptoms of central nervous system stimulation, including convulsions, should be treated with diazepam, given slowly intravenously. Phenothiazine derivatives and central nervous system stimulants should be avoided. Hypotension and vascular collapse should be treated with intravenous fluids and, if necessary, blood pressure titration with an intravenous infusion of a dilute pressor agent. It should be noted that adrenergic agents may produce a markedly increased pressor response.

Respiration should be supported by appropriate measures, including management of the airway, use of supplemental oxygen, and mechanical ventilatory assistance, as required.

Body temperature should be monitored closely. Intensive management of hyperpyrexia may be required. Maintenance of fluid and electrolyte balance is essential.

How should I store and handle SELEGILINE HYDROCHLORIDE?

Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140Selegiline Hydrochloride Capsules, USP are available containing 5 mg of selegiline hydrochloride. Each opaque white capsule is printed with S 700.They are available as:NDC 67253-700-06 bottles of 60 capsules.Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]All brand names listed are registered trademarks of their respective owners and are not trademarks of Par Pharmaceutical.Manufactured by:ULTRAtab Laboratories, Inc.Highland, NY 12528 USADistributed by:Par PharmaceuticalChestnut Ridge, NY 10977Revised: 03/17300 172 990 140

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

The mechanisms accounting for selegiline’s beneficial adjunctive action in the treatment of Parkinson’s disease are not fully understood. Inhibition of monoamine oxidase, type B, activity is generally considered to be of primary importance; in addition, there is evidence that selegiline may act through other mechanisms to increase dopaminergic activity.

Selegiline is best known as an irreversible inhibitor of monoamine oxidase (MAO), an intracellular enzyme associated with the outer membrane of mitochondria. Selegiline inhibits MAO by acting as a ‘suicide’ substrate for the enzyme; that is, it is converted by MAO to an active moiety which combines irreversibly with the active site and/or the enzyme’s essential FAD cofactor. Because selegiline has greater affinity for type B rather than for type A active sites, it can serve as a selective inhibitor of MAO type B if it is administered at the recommended dose.

MAOs are widely distributed throughout the body; their concentration is especially high in liver, kidney, stomach, intestinal wall, and brain. MAOs are currently subclassified into two types, A and B, which differ in their substrate specificity and tissue distribution. In humans, intestinal MAO is predominantly type A, while most of that in brain is type B.

In CNS neurons, MAO plays an important role in the catabolism of catecholamines (dopamine, norepinephrine and epinephrine) and serotonin. MAOs are also important in the catabolism of various exogenous amines found in a variety of foods and drugs. MAO in the GI tract and liver (primarily type A), for example, is thought to provide vital protection from exogenous amines (e.g., tyramine) that have the capacity, if absorbed intact, to cause a ‘hypertensive crisis,’ the so-called ‘cheese reaction.’ (If large amounts of certain exogenous amines gain access to the systemic circulation — e.g., from fermented cheese, red wine, herring, over-the-counter cough/cold medications, etc.— they are taken up by adrenergic neurons and displace norepinephrine from storage sites within membrane-bound vesicles. Subsequent release of the displaced norepinephrine causes the rise in systemic blood pressure, etc.)

In theory, since MAO-A of the gut is not inhibited, patients treated with selegiline at a dose of 10 mg a day should be able to take medications containing pharmacologically active amines and consume tyramine-containing foods without risk of uncontrolled hypertension. Although rare, a few reports of hypertensive reactions have occurred in patients receiving selegiline hydrochloride at the recommended dose, with tyramine-containing foods. In addition, one case of hypertensive crisis has been reported in a patient taking the recommended dose of selegiline and a sympathomimetic medication, ephedrine. The pathophysiology of the ‘cheese reaction’ is complicated and, in addition to its ability to inhibit MAO-B selectively, selegiline’s relative freedom from this reaction has been attributed to an ability to prevent tyramine and other indirect acting sympathomimetics from displacing norepinephrine from adrenergic neurons. However, until the pathophysiology of the cheese reaction is more completely understood, it seems prudent to assume that selegiline can ordinarily only be used safely without dietary restrictions at doses where it presumably selectively inhibits MAO-B (e.g., 10 mg/day).

In short, attention to the dose dependent nature of selegiline’s selectivity is critical if it is to be used without elaborate restrictions being placed on diet and concomitant drug use although, as noted above, a few cases of hypertensive reactions have been reported at the recommended dose. (See and .)

It is important to be aware that selegiline may have pharmacological effects unrelated to MAO-B inhibition. As noted above, there is some evidence that it may increase dopaminergic activity by other mechanisms, including interfering with dopamine re-uptake at the synapse. Effects resulting from selegiline administration may also be mediated through its metabolites. Two of its three principal metabolites, amphetamine and methamphetamine, have pharmacological actions of their own; they interfere with neuronal uptake and enhance release of several neurotransmitters (e.g., norepinephrine, dopamine, serotonin). However, the extent to which these metabolites contribute to the effects of selegiline are unknown.

Rationale for the Use of a Selective Monoamine Oxidase Type B Inhibitor in Parkinson’s Disease:

With the passage of time, due to the progression of the disease and/or the effect of sustained treatment, the efficacy and quality of the therapeutic response to levodopa diminishes. Thus, after several years of levodopa treatment, the response, for a given dose of levodopa, is shorter, has less predictable onset and offset (i.e., there is ‘wearing off’), and is often accompanied by side effects (e.g., dyskinesia, akinesias, on-off phenomena, freezing, etc.).

This deteriorating response is currently interpreted as a manifestation of the inability of the ever decreasing population of intact nigrostriatal neurons to synthesize and release adequate amounts of dopamine.

MAO-B inhibition may be useful in this setting because, by blocking the catabolism of dopamine, it would increase the net amount of dopamine available (i.e., it would increase the pool of dopamine). Whether or not this mechanism or an alternative one actually accounts for the observed beneficial effects of adjunctive selegiline is unknown.

Selegiline’s benefit in Parkinson’s disease has only been documented as an adjunct to levodopa/carbidopa. Whether or not it might be effective as a sole treatment is unknown, but past attempts to treat Parkinson’s disease with non-selective MAOI monotherapy are reported to have been unsuccessful. It is important to note that attempts to treat Parkinsonian patients with combinations of levodopa and currently marketed non-selective MAO inhibitors were abandoned because of multiple side effects including hypertension, increase in involuntary movement, and toxic delirium.

PHARMACOKINETIC INFORMATION (ABSORPTION, DISTRIBUTION, METABOLISM AND ELIMINATION-ADME):

The absolute bioavailability of selegiline following oral dosing is not known; however selegiline undergoes extensive metabolism (presumably attributable to presystemic clearance in gut and liver). The major plasma metabolites are N-desmethylselegiline, L-amphetamine and L-methamphetamine. Only N-desmethylselegiline has MAO-B inhibiting activity. The peak plasma levels of these metabolites following a single oral dose of 10 mg are from 4 to almost 20 times greater than that of the maximum plasma concentration of selegiline [1 ng/mL]. The maximum concentrations of amphetamine and methamphetamine, however, are far below those ordinarily expected to produce clinically important effects.

Single oral dose studies do not predict multiple dose kinetics, however, at steady state, the peak plasma level of selegiline is 4 fold that obtained following a single dose. Metabolite concentrations increase to a lesser extent, averaging 2 fold that seen after a single dose.

The bioavailability of selegiline is increased 3 to 4 fold when it is taken with food.

The extent of systemic exposure to selegiline at a given dose varies considerably among individuals. Estimates of systemic clearance of selegiline are not available. Following a single oral dose, the mean elimination half-life of selegiline is two hours. Under steady state conditions, the elimination half-life increases to ten hours.

Because selegiline’s inhibition of MAO-B is irreversible, it is impossible to predict the extent of MAO-B inhibition from steady state plasma levels. For the same reason, it is not possible to predict the rate of recovery of MAO-B activity as a function of plasma levels. The recovery of MAO-B activity is a function of de novo protein synthesis; however, information about the rate of de novo protein synthesis is not yet available. Although platelet MAO-B activity returns to the normal range within 5 to 7 days of selegiline discontinuation, the linkage between platelet and brain MAO-B inhibition is not fully understood nor is the relationship of MAO-B inhibition to the clinical effect established (See ).

Special Populations:

Renal Impairment:

Hepatic Impairment:

Age:

Gender:

Non-Clinical Toxicology

Selegiline hydrochloride capsules are contraindicated in patients with a known hypersensitivity to this drug.

Selegiline hydrochloride capsules are contraindicated for use with meperidine (DEMEROL & other trade names). This contraindication is often extended to other opioids. (See )

Selegiline should not be used at daily doses exceeding those recommended (10 mg/day) because of the risks associated with non-selective inhibition of MAO. (See .)

The selectivity of selegiline for MAO-B may not be absolute even at the recommended daily dose of 10 mg a day. Rare cases of hypertensive reactions associated with ingestion of tyramine-containing foods have been reported in patients taking the recommended daily dose of selegiline. The selectivity is further diminished with increasing daily doses. The precise dose at which selegiline becomes a non-selective inhibitor of all MAO is unknown, but may be in the range of 30 to 40 mg a day.

Severe CNS toxicity associated with hyperpyrexia and death have been reported with the combination of tricyclic antidepressants and non-selective MAOIs (NARDIL, PARNATE). A similar reaction has been reported for a patient on amitriptyline and selegiline hydrochloride capsules. Another patient receiving protriptyline and selegiline hydrochloride capsules developed tremors, agitation, and restlessness followed by unresponsiveness and death two weeks after selegiline hydrochloride capsules were added. Related adverse events including hypertension, syncope, asystole, diaphoresis, seizures, changes in behavioral and mental status, and muscular rigidity have also been reported in some patients receiving selegiline hydrochloride capsules and various tricyclic antidepressants.

Serious, sometimes fatal, reactions with signs and symptoms that may include hyperthermia, rigidity, myoclonus, autonomic instability with rapid fluctuations of the vital signs, and mental status changes that include extreme agitation progressing to delirium and coma have been reported with patients receiving a combination of fluoxetine hydrochloride (PROZAC) and non-selective MAOIs. Similar signs have been reported in some patients on the combination of selegiline hydrochloride capsules (10 mg a day) and selective serotonin reuptake inhibitors including fluoxetine, sertraline and paroxetine.

Since the mechanisms of these reactions are not fully understood, it seems prudent, in general, to avoid this combination of selegiline hydrochloride capsules and tricyclic antidepressants as well as selegiline hydrochloride capsules and selective serotonin reuptake inhibitors. At least 14 days should elapse between discontinuation of selegiline hydrochloride capsules and initiation of treatment with a tricyclic antidepressant or selective serotonin reuptake inhibitors. Because of the long half-lives of fluoxetine and its active metabolite, at least five weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses) should elapse between discontinuation of fluoxetine and initiation of treatment with selegiline hydrochloride capsules.

The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see ). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and selegiline hydrochloride capsules and selective serotonin reuptake inhibitors and selegiline hydrochloride capsules. (See for details.) One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).

Some patients given selegiline may experience an exacerbation of levodopa associated side effects, presumably due to the increased amounts of dopamine reaction with super sensitive post-synaptic receptors. These effects may often be mitigated by reducing the dose of levodopa/carbidopa by approximately 10 to 30%.

The decision to prescribe selegiline should take into consideration that the MAO system of enzymes is complex and incompletely understood and there is only a limited amount of carefully documented clinical experience with selegiline. Consequently, the full spectrum of possible responses to selegiline may not have been observed in pre-marketing evaluation of the drug. It is advisable, therefore, to observe patients closely for atypical responses.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Disclaimer: